Changing utilization of cardiovascular drugs during the course of Alzheimer's disease
Identifikátory výsledku
Kód výsledku v IS VaVaI
<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11120%2F20%3A43919430" target="_blank" >RIV/00216208:11120/20:43919430 - isvavai.cz</a>
Výsledek na webu
<a href="https://doi.org/10.1016/j.ijcard.2019.11.135" target="_blank" >https://doi.org/10.1016/j.ijcard.2019.11.135</a>
DOI - Digital Object Identifier
<a href="http://dx.doi.org/10.1016/j.ijcard.2019.11.135" target="_blank" >10.1016/j.ijcard.2019.11.135</a>
Alternativní jazyky
Jazyk výsledku
angličtina
Název v původním jazyce
Changing utilization of cardiovascular drugs during the course of Alzheimer's disease
Popis výsledku v původním jazyce
The relationship between cardiovascular diseases (CVD) and cognitive disorders, such as Alzheimer's disease (AD), the most common type of dementia, has been recently receiving major interest. This interest is focused around the role of cardiovascular risk factors and CVD in the etiology of AD, implying that their improved prevention and treatment may serve as a potential strategy to decrease the incidence of AD. Additionally, management of CVD in patients with AD is complicated by lacking clinical guidelines, as older individuals with conditions such as AD are largely excluded from randomized controlled trials.
Název v anglickém jazyce
Changing utilization of cardiovascular drugs during the course of Alzheimer's disease
Popis výsledku anglicky
The relationship between cardiovascular diseases (CVD) and cognitive disorders, such as Alzheimer's disease (AD), the most common type of dementia, has been recently receiving major interest. This interest is focused around the role of cardiovascular risk factors and CVD in the etiology of AD, implying that their improved prevention and treatment may serve as a potential strategy to decrease the incidence of AD. Additionally, management of CVD in patients with AD is complicated by lacking clinical guidelines, as older individuals with conditions such as AD are largely excluded from randomized controlled trials.
Klasifikace
Druh
O - Ostatní výsledky
CEP obor
—
OECD FORD obor
30103 - Neurosciences (including psychophysiology)
Návaznosti výsledku
Projekt
—
Návaznosti
V - Vyzkumna aktivita podporovana z jinych verejnych zdroju
Ostatní
Rok uplatnění
2020
Kód důvěrnosti údajů
S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů